WST Stock Builds on GLP-1 Growth, Annex 1 and Margins in Focus

West Pharmaceutical Services, Inc. WST is well-positioned for growth, backed by the robust GLP-1 related demand and its expansion plans. However, pricing headwinds and tariff risks are concerning.Shares of this Zacks Rank #2 (Buy) company have lost 32.5% so far this year compared with the industry's 0.6% decline. The S&P...